BC-CfE submitted Health Canada “Special Access Program” application to provide two investigational HIV drugs to six patients resistant to all other therapies. Health Canada denies the BC-CfE access and the BC-CfE publicly campaigns for access. Health Canada reverses its decision and the BC-CfE is first to prescribe the combination of TMC114 (darunavir) and TMC125 (etravirine) together to the remaining five patients.
BC-CfE’s research lab demonstrated the effect of impact of human and virus genetics in the response to HAART treatments.
BC-CfE launched large cohort of women in sex work to examine their sexual health and HIV needs and barriers to care.
